Advanced Renal Cell Carcinoma: Patient-Specific Recommendations From an International Panel of Experts

Bradley A. McGregor, MD, reviews and summarizes country- and patient-specific treatment recommendations from an international panel of experts based on recent practice-changing clinical trial results in RCC.
Bradley A. McGregor, MD
Released: February 27, 2018 Expiration: No longer available for credit

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Consider treatment guidelines, efficacy, and safety evidence, along with patient characteristics and preferences to individualize therapeutic strategies for newly diagnosed advanced RCC
  • Plan treatment strategies for patients with advanced RCC after progression based on available data and treatment guidelines
  • Determine the optimal sequence or combination of agents with a goal of achieving remission for as long as possible
  • Manage adverse events of new agents to minimize impact to quality of life and maintain efficacy for your patients with RCC

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by an educational grant from
Ipsen Biopharmaceuticals, Inc.

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Bradley A. McGregor, MD

Instructor of Medicine
Department of Medicine
Harvard Medical School
Clinical Director
Lank Cancer for Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Bradley A. McGregor, MD, has disclosed that he has received consulting fees from Astellas, Exelixis, Genentech, and Seattle Genetics.

Staff

Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no real or apparent conflicts of interest to report.
Brandon May

Editorial Contributor

Brandon May has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
Kristen M. Rosenthal, PhD

Managing Editor

Kristen Rosenthal, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for medical oncologists and other clinicians involved in the care of patients with advanced RCC.

Goal

The goal of this activity is to improve participants’ competence in integrating new agents into the treatment of patients with advanced RCC.

Physician Continuing Medical Education


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 27, 2018, through February 26, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

From ASCO 2020: analysis by Daniel P. Petrylak, MD, and Elizabeth R. Plimack, MD, MS, of key studies in renal cell carcinoma, urothelial carcinoma, and prostate cancer from CCO

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 1, 2020 Expired: August 31, 2021

Commentary from CCO on the use of high-dose interleukin-2 (HD IL-2) in patients with renal cell carcinoma in 2020

Brendan D. Curti, MD Released: August 24, 2020

From Clinical Care Options (CCO), an on-demand Webcast on immuno-oncology biomarkers that are key to optimal cancer treatment across multiple tumors

John L. Marshall, MD
Program Director
Jamie E. Chaft, MD Scot Niglio, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 24, 2020 Expired: August 23, 2021

From Clinical Care Options (CCO), watch video of an expert discussion of NTRK fusion testing and TRK inhibitor use in solid cancers

George D. Demetri, MD
Program Director
person default Alexander Drilon, MD Pashtoon Kasi, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 21, 2020 Expired: August 20, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue